MEDICINOVA INC (MNOV)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.63+0.62%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · MNOV
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 221.2% |
| Our one-year growth estimate | diamond | 6.2% |
Growth built into the price is above our model estimate.
The price assumes 215.1 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
MNOV — M&A activity — Termination of a Material Definitive Agreement
Dated 2026-09-02
Termination of a Material Definitive Agreement. Termination of Standby Equity Purchase Agreement On August 31, 2026, MediciNova, Inc. (the “Company”) delivered to YA II PN, LTD. (“Yorkville”), a Notice of Termination, informing Yorkville of the Company’s election to terminate the Standby Equity Purchase Agreement, dated as of July 30, 2025, by and between the Company and Yorkville (the “SEPA”), as required under Section 9.01(b) of the SEPA. Termination of the SEPA will become effective as of…
Why it matters: Revenue growth below the median would signal weakening in the healthcare sector's growth phase.
Worry ifQ2 revenue growth reported below the median growth rate for the sector.
Less concerning ifQ2 revenue growth remains above the median growth rate for the sector.
Why it matters: High operating costs may show management struggles to control spending. This affects financial health.
Worry ifOperating costs were over $16.2 million for the fiscal year 2026.
Less concerning ifOperating expenses were at or below $16.2 million for the fiscal year 2026.
Why it matters: The earnings report will show if the company is improving its financial situation. Investors will look for signs of recovery or continued losses.
Watch forThe earnings report shows a smaller loss than last quarter. This means things are getting better.
Also watch forThe earnings report shows a larger loss than last quarter. This means things are getting worse.
Why it matters: If health care sector revenue growth speeds up, it could benefit Medicinova. This signals a healthier market.
Supportive ifHealth care sector revenue growth exceeds 9% year over year.
Worry ifHealth care sector revenue growth remains below 9% year over year.
Why it matters: Less operating losses show better cost control. This may help financial stability.
Supportive ifOperating losses improve to less than -$2.5 million in Q3 2026.
Worry ifOperating losses worsen to more than -$2.5 million in Q3 2026.
Why it matters: The termination may affect funding options and future growth plans. Investors need clarity on the next steps.
Watch forManagement announces a new funding deal or a different source of money.
Also watch forNo new financing options are announced, leading to concerns about cash flow.
Why it matters: Revenue growth shows that clinical and development work is going well. It helps cover losses.
Supportive ifQ3 revenue from clinical activities grows more than 20% compared to Q2.
Worry ifQ3 revenue from clinical activities grows less than 10% compared to Q2.
Why it matters: Staying under $16.2 million shows good cost management. This helps reduce operating losses.
Supportive ifOperating costs were less than $16.2 million in Q3.
Worry ifOperating expenses were over $16.2 million for Q3. This shows poor cost control.
Why it matters: A drop in momentum shows deeper problems in the company's performance.
Worry ifCompany momentum score falls below -50.0 after the next earnings refresh.
Less concerning ifCompany momentum score is above -45.0. This means recovery is happening.
Why it matters: A lower composite score means the company is not doing well. It also shows that investors feel less confident.
Worry ifComposite insight score falls below -5.0 after the next earnings refresh.
Less concerning ifComposite insight score is above -2.8. This shows improvement.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$144 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $472 loss on $10,000 · 4.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,457 loss on $10,000 · 34.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.